Verrica Pharmaceuticals Inc. (1NE.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:01AM CEST. Market open.
Loading interactive chart…
- GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a minimal impact on Verrica’s cash position Common warts is one of the largest and most underserved patient populations in medical dermatology with a prevalence of ~22M in the U.S. and no FDA approved products; Verrica believes com
- GuruFocus.com
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore Verrica Pharmaceuticals' financial performance, strategic partnerships, and operational insights from the first quarter of 2024.
- GuruFocus.com
Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
Exploring Verrica's Financial Outcomes and Strategic Developments in the First Quarter
© 2024 Yahoo. All rights reserved.